While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation.
Background/Objectives
Zepbound (tirzepatide) is among the most effective obesity medicines for weight reduction, in both clinical trial and real-world settings. Product marketing largely centers on weight-loss magnitude, which may reinforce the expectation that larger reductions are always better.
Methods
Using de-identified EHRs, we compared 1,039 Zepbound initiators (1.7%) whose first-year weight loss reached ≥30% (“excessive weight loss”) with 20,668 Zepbound initiators (34.7%) who lost 5%-15% (“moderate weight loss”). After 1:4 propensity score matching (837 versus 3,348 patients), large language model (LLM)-curation extracted 24 adverse events that physician notes explicitly attributed to weight loss.
Results
The rate of any weight loss-attributable adverse event was significantly higher with excessive weight loss, at 39.4 versus 14.4 per 100 patient-years, representing 294 (35.1%) versus 479 (14.3%) patients (rate ratio [RR]: 2.78, 95% confidence interval [CI] 2.40-3.21; P<0.001). Falls, weakness, syncope, alopecia, low blood pressure, gastro-intestinal symptoms, and muscle loss were significantly enriched in the excessive weight loss cohort after false-discovery-rate correction (all q<0.001). Hospitalization was documented in 215 patients (25.7%) with excessive weight loss versus 527 patients (15.7%) with moderate weight loss (RR: 1.63, 1.42-1.87), Intensive care admission in 44 patients (5.3%) versus 77 patients (2.3%) (RR: 2.29, 1.59-3.28) (both q<0.001), and newly recorded heart-failure diagnosis in 11 patients (1.3%) versus 16 patients (0.5%) (RR: 2.75, 1.28-5.91; q=0.028). Laboratory tests and vital measurements recorded within 30 days of the lowest achieved body weight corroborated these findings, including significant enrichments in systolic (<90 mmHg) or diastolic (<60 mmHg) hypotension (RR: 3.19, 95% CI 2.51-4.05), anemia (RR: 1.86, 1.45-2.40), hyponatremia (RR: 2.74, 1.63-4.60), hypokalemia (RR: 2.34, 1.58-3.46), hypocalcemia (RR: 3.25, 1.87-5.68), hypoalbuminemia (RR: 2.93, 1.83-4.70), and hypoproteinemia (RR: 3.89, 2.32-6.52) in excessive weight loss patients (all q<0.001).
Conclusions
While residual confounding and documentation differences may contribute to some real-world associations, the significantly greater burden of adverse events, hospitalization rates, laboratory test anomalies, and vital-sign abnormalities among Zepbound patients with excessive weight loss warrants further investigation. These findings support moving towards individualized weight-loss goals, motivate the need for prospective studies into the risk-benefit profile of Zepbound, and call for closer scrutiny of pharmaceutical marketing to clarify that the greatest weight reduction may not translate into better health outcomes.
Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.